• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » ICD: New study shows low use, high benefit in older HF patients

ICD: New study shows low use, high benefit in older HF patients

June 23, 2015 By Fink Densford

ICD: New study shows low use, high benefit in older HF patientsA new study released in the Journal of the American Medical Association today reported that implantable cardioverter-defibrillators may be underutilized in elderly patients.

Data from the 10,318-patient study, partially supported by Boston Scientific (NYSE:BSX), revealed that only 8.1% of eligible patients over 65 received ICDs within 1 year after experiencing a heart attack, despite the fact that implantation was associated with a 33% lower 2-year mortality rate.

“We looked at the association between receiving an ICD and death to compare the benefit for patients over the age of 80 with the same benefit for patients under the age of 80 and we found that there’s really a consistent benefit for ICD therapy across both age groups,” lead author Sean Pokorney, of the Duke University School of Medicine told MassDevice.com.

Pokorney said that current guidelines, which recommend a 40-day waiting period after a heart attack before ICD implantation, may be having a negative effect on implantation rates.

“The optimal timing for implanting a defibrillator is still in question, but current guidelines recommend that patients wait at least 40 days after their heart attack. If the patient’s heart is still having trouble pumping blood after 40 days, they would be eligible. But a lot can happen in that 40 days,” Pokorney said in a press release.

Pokorney said the study looked at patients during that 40-day period to see if they were healing, and no longer required ICDs.

“One of our questions was, are our patients hearts recovering? We know from historical data that it happens, but it’s relatively uncommon. So we looked at patients who had the largest heart attacks; patients who had the weakest hearts at the time of their heart attack; patients that are least likely to have recovery of heart function. Even among these patients, the rates of ICD implantation were about 1 in 10,” Pokorney said.

How often patients interact with their clinicians and health care workers affects the rate of ICD implantation as well, Pokorney said.

“One of the key findings was that patients who had more contact with the healthcare system were more likely to receive ICDs,” Pokorney said. “That was seen in the form of early cardiology follow-ups. Patients who have cardiology visits within 2 weeks of their heart attack have higher rates of ICD implantations. Patients that came back to the hospital for heart attacks of heart failure had higher rates as well.”

Pokorney said that while no one expects a 100% implantation rate, an increase in implantation rate among older patients could save lives.

“I think one thing that providers should understand is that this study shows that age alone should not be a contraindication to ICD implantation,” Pokorney said. “Even though we may need to refine our patient selection process, and who will benefit the most, we don’t feel that age should be a contraindication.”

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Structural Heart Tagged With: Boston Scientific

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy